Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)
- Author: Zachary Reyes Mar 15, 2017,
Mar 15, 2017, 15:49
The stock was range-bound for the rest of the session and closed down by 1.07 at $2.46 with volume at a 6-month high. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of -40.09%. Two equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $11.13. (NASDAQ:ARLZ) holds price to book ratio of 1.06 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach.
The Stock now has the market capitalization of $161.4 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 14.76% and monthly volatility of 6.97% respectively. The firm attains analyst recommendation of 2.00 out of 1-5 scale with week's performance of -32.79%.
Aralez Pharmaceuticals Inc.is now showing 45.5% EPS growth this year. NASDAQ:ARLZ may hit a high of $10. This estimate is provided by 2 analysts. According to them, the median (average) EPS the company could deliver is -0.26/share.
For the year, the company reported that its loss widened to $103 million, or $1.74 per share. The company beat the analyst EPS Estimate with the difference of $0.07. Thus the company showed an Earnings Surprise of 18.9 Percent. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) 's institutional ownership was registered as 46.30%, while insider ownership was 1.10%. (NASDAQ:ARLZ) could bring EPS of $-0.37/share. The last closing price is down -54.94% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time.
On the sales side, ARLZ's revenues are expected to retreat to $5.97M versus prior year's Q4 result of $5.97M. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -44.22%.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has a market capitalization of 162.77 Million. The company rocked its 52-Week High of $6.8 on Sep 12, 2016 and touched its 52-Week Low of $2.37 on Mar 13, 2017. The stock traded with the volume of 6.24 Million shares in the last trading session. ARLZ has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0 and Price to Free Cash Flow (P/FCF) value of 0. The Monthly and Yearly performances are -42.66 percent and -58.66 percent respectively. According to WSJ analysis, the Q4 2016 current estimates trends were for $-0.26 as compared to the next year Q1 current trend of $-0.25. Total debt to equity ratio of the company for most recent quarter is 0.00 whereas long term debt to equity ratio for most recent quarter is 0.50.
The Company got Initiated by Guggenheim on 10-Feb-16 to Buy. The Insider Ownership of the company now is 1.1 percent, and Institutional Ownership is 46.3 percent.